急性髓系白血病中的突变亚型转换 - Suppr

mutation subtype switch in acute myeloid leukemia.

作者信息

Podvin Benjamin, Joudinaud Romane, Roumier Christophe, Boudry Augustin, Farnault Laure, Dantec Mélinda, Berthon Céline, Dumezy Florent, Goursaud Laure, Bucci Maxime, Preudhomme Claude, Duployez Nicolas

机构信息

CHU Lille, Laboratory of Hematology; Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.

CHU Lille, Laboratory of Hematology.

出版信息

Haematologica. 2025 Aug 1;110(8):1887-1890. doi: 10.3324/haematol.2024.286916. Epub 2025 Mar 20.

DOI:10.3324/haematol.2024.286916

PMID:40109189

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12358776/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f76/12358776/24e034d6c2dd/1101887.fig1.jpg

相似文献

mutation subtype switch in acute myeloid leukemia.急性髓系白血病中的突变亚型转换

Haematologica. 2025 Aug 1;110(8):1887-1890. doi: 10.3324/haematol.2024.286916. Epub 2025 Mar 20.

Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring Triple Mutations and the Potential Prognostic Value of .携带三重突变的急性髓系白血病患者的临床特征与预后及……的潜在预后价值

Cancer Control. 2025 Jan-Dec;32:10732748251359836. doi: 10.1177/10732748251359836. Epub 2025 Jul 17.

Mutant NPM1 maintains RASGRP3 protein stability via interaction with MID1 to promote acute myeloid leukemia cell proliferation and autophagy.突变型 NPM1 通过与 MID1 相互作用维持 RASGRP3 蛋白稳定性，从而促进急性髓系白血病细胞增殖和自噬。

J Leukoc Biol. 2023 May 2;113(5):504-517. doi: 10.1093/jleuko/qiad023.

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.通过下一代测序检测NPM1突变型急性髓系白血病中的微小残留病

Mod Pathol. 2014 Nov;27(11):1438-46. doi: 10.1038/modpathol.2014.57. Epub 2014 Apr 18.

Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.新诊断的伴有FLT3-酪氨酸激酶结构域突变的急性髓系白血病患者的预后：NPM1共突变的预后意义

Cancer. 2025 Aug 15;131(16):e70032. doi: 10.1002/cncr.70032.

Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with mutation.

Leuk Lymphoma. 2025 Aug;66(8):1487-1497. doi: 10.1080/10428194.2025.2482130. Epub 2025 Mar 31.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).一个单突变数学模型可以解释伴有核磷蛋白（NPM1）突变的急性髓系白血病的年龄发病率。

Haematologica. 2008 Aug;93(8):1219-26. doi: 10.3324/haematol.13209. Epub 2008 Jul 4.

Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.伴有 NPM1 基因突变的急性髓系白血病或骨髓增生异常综合征中的相关白血病免疫表型和可测量疾病检测。

Cytometry B Clin Cytom. 2019 Jan;96(1):67-72. doi: 10.1002/cyto.b.21744. Epub 2018 Nov 12.

[Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].[基于下一代测序的基因分型与NPM1突变型急性髓系白血病MICM特征的关联]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):56-60. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.010.

NRF2 maintains redox balance via ME1 and NRF2 inhibitor synergizes with venetoclax in NPM1-mutated acute myeloid leukemia.NRF2通过ME1维持氧化还原平衡，且NRF2抑制剂与维奈托克在NPM1突变的急性髓系白血病中具有协同作用。

Cancer Metab. 2025 Jun 18;13(1):32. doi: 10.1186/s40170-025-00401-6.

本文引用的文献

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.急性髓系白血病患者中通过纠错测序评估的多靶点可测量残留病：一项ALFA研究。

Blood Cancer J. 2024 Jun 13;14(1):97. doi: 10.1038/s41408-024-01078-8.

Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.急性髓系白血病微量残留病的单细胞基因表型分析。

Sci Adv. 2023 Sep 22;9(38):eadg0488. doi: 10.1126/sciadv.adg0488. Epub 2023 Sep 20.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.伴有复发或难治性 AML 的 NPM1 突变患者的临床结局。

Blood Adv. 2023 Mar 28;7(6):933-942. doi: 10.1182/bloodadvances.2022008316.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.国际髓系肿瘤和急性白血病分类：整合形态学、临床和基因组数据。

Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。

Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.

Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.急性髓系白血病中罕见NPM1突变的分子异质性与可测量残留病：GBMHM研究组的全国性经验

Leukemia. 2022 May;36(5):1390-1400. doi: 10.1038/s41375-022-01534-z. Epub 2022 Mar 7.

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.AML 中导致异常细胞质核仁磷酸蛋白的新型 NPM1 外显子 5 突变和基因融合。

Blood. 2021 Dec 23;138(25):2696-2701. doi: 10.1182/blood.2021012732.

Pitfalls in the molecular follow up of mutant acute myeloid leukemia.突变型急性髓系白血病分子随访中的陷阱

Haematologica. 2018 Oct;103(10):e486-e488. doi: 10.3324/haematol.2018.192104. Epub 2018 Jun 14.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.诱导后微小残留病预测 NPM1 突变的急性髓系白血病患者异基因造血干细胞移植的疗效和获益：法国急性白血病协会研究组研究。

J Clin Oncol. 2017 Jan 10;35(2):185-193. doi: 10.1200/JCO.2016.67.1875. Epub 2016 Nov 14.

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?急性髓系白血病（AML）中NPM1基因突变类型的转变：复发还是继发性AML？

Blood Cancer J. 2014 Jun 27;4(6):e221. doi: 10.1038/bcj.2014.42.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

mutation subtype switch in acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献